目的 探討復方腦肽節(jié)苷脂聯(lián)合依達拉奉治療急性腦梗死的臨床療效以及其對患者血清中樞神經(jīng)特異性蛋白（S100β）、神經(jīng)元特異性烯醇化酶（NSE）、8異前列腺素F_2α（8-iso-PGF_2α）和丙二醛（MDA）水平的影響。方法 選取2018年1月-2019年12月山東省蓬萊市人民醫(yī)院收治的120例急性腦梗死患者作為研究對象，按照治療方法將患者分成對照組（n=60）和觀察組（n=60）。對照組患者靜脈滴注依達拉奉注射液，將30 mg加入250 mL生理鹽水中均勻混合后給藥，2次/d。觀察組在對照組的基礎上靜脈滴注復方腦肽節(jié)苷脂注射液，將10 mL加入250 mL生理鹽水中充分稀釋后給藥，1次/d。兩組連續(xù)治療14 d。觀察兩組患者的臨床療效，同時比較兩組治療前后的美國國立衛(wèi)生研究院卒中量表（NIHSS）評分、腦卒中專門化生活質量量表（SS-QOL）評分，以及血清S100β、NSE、8-iso-PGF_2α和MDA水平。結果 治療后，觀察組總有效率為95.0%，顯著高于對照組的81.7%（P<0.05）。治療后，兩組NIHSS評分均顯著降低，SS-QOL評分則均顯著升高（P<0.05）；觀察組NIHSS和SS-QOL評分顯著優(yōu)于對照組（P<0.05）。治療后，兩組血清S100β、NSE、8-iso-PGF_2α和MDA水平均顯著低于治療前（P<0.05），且觀察組血清S100β、NSE、8-iso-PGF_2α和MDA水平顯著低于對照組（P<0.05）。結論 復方腦肽節(jié)苷脂聯(lián)合依達拉奉對急性腦梗死患者具有確切的臨床療效，對患者腦神經(jīng)損傷、神經(jīng)功能缺損及生存質量均有明顯改善作用，可進一步降低血中8-iso-PGF_2α、MDA的水平，且安全性較好。

Objective To investigate the clinical efficacy of compound brain peptide glycoside combined with edaravone in treatment of acute cerebral infarction and its effect on patients' serum levels of S100β, NSE, 8-iso-PGF_2α, and MDA. Methods A total of 120 patients with acute cerebral infarction admitted to Penglai People's Hospital of Shandong Province from January 2018 to December 2019 were selected as the research subjects, and the patients were divided into control group (n=60) and observation group (n=60) according to the treatment methods. Patients in the control group was intravenously injected with Edaravone Injection, 30 mg was added into 250 mL normal saline, and then evenly mixed, twice daily. Patients in the observation group was additionally injected with Compound Porcine Cerebroside and Ganglioside Injection intravenously, adding 10 mL into 250 mL normal saline and giving the injection after full dilution, once daily. Two groups were treated continuously for 14 days. Clinical efficacy of two groups was observed. The NIHSS score, SS-QOL score, serum S100β, NSE, 8-iso-PGF_2α, and MDA levels before and after treatment were compared between two groups. Results After treatment, the total effective rate of observation group was 95.0%, significantly higher than 81.7% of control group (P<0.05). After treatment, NIHSS score in two groups was significantly decreased, while SS-QOL score was increased (P<0.05). And NIHSS and SS-QOL scores in the observation group were significantly better than those in the control group (P<0.05). After treatment, the serum levels of S100β, NSE, 8-iso-PGF_2α, and MDA in two groups were significantly lower than those before treatment (P<0.05), and the serum levels of S100β, NSE, 8-iso-PGF_2α, and MDA in observation group were significantly lower than those in control group (P<0.05). Conclusions Compound brain peptide glycoside combined with edaravone has a definite clinical effect on patients with acute cerebral infarction, and can significantly improve the brain nerve injury, neurological function deficit and quality of life of patients, and can further reduce the levels of 8-iso-PGF_2αand MDA in blood, with good safety.

R971